Tulathromycin

Tulathromycin
Clinical data
AHFS/Drugs.com	International Drug Names
ATCvet code	QJ01FA94 (WHO) ;
Identifiers
	IUPAC name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-Ο-methyl-4-C-[(propylamino)methyl]-α-L-ribo-hexopyrano-syl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]-oxy]-1-oxa-6-azacyclopentadecan-15-one;
CAS Number	217500-96-4;
ChemSpider	24583287 ;
UNII	Q839I13422;
KEGG	D06258 ;
CompTox Dashboard (EPA)	DTXSID60274184 ;
ECHA InfoCard	100.166.454
Chemical and physical data
Formula	C41H79N3O12
Molar mass	806.092 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCNCC1(C(OC(CC1(C)OC)OC2C(C(C(CC(NC(C(C(C(OC(=O)C2C)CC)(C)O)O)C)C)(C)O)OC3C(C(CC(O3)C)N(C)C)O)C)C)O;
	InChI InChI=1S/C40H77N3O12/c1-15-17-41-21-40(49)27(8)52-30(20-38(40,10)50-14)54-32-24(5)34(55-36-31(44)28(43(12)13)18-23(4)51-36)37(9,47)19-22(3)42-26(7)33(45)39(11,48)29(16-2)53-35(46)25(32)6/h22-34,36,41-42,44-45,47-49H,15-21H2,1-14H3/t22-,23-,24+,25-,26-,27+,28+,29-,30+,31-,32+,33-,34-,36+,37-,38-,39-,40+/m1/s1 ; Key:HWATWVYEWMIMSO-FROLMUNOSA-N ;
	(verify)

Tulathromycin is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs. It is marketed by Pfizer Inc. under the brand name Draxxin.

It is supplied as a solution for injection containing 100 mg of the drug. [1]

On 16 July 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted positive opinions, recommending the granting of marketing authorizations for the veterinary medicinal products Increxxa and Tulinovet solutions for injection for cattle, pigs and sheep.[2][3] The applicant for Increxxa is Elanco GmbH.[2] The applicant for Tulinovet is VMD N.V.[3]

References

Draxxin Archived 2006-10-24 at the Wayback Machine at draxxin.com
"Increxxa: Pending EC decision". European Medicines Agency. 17 July 2020. Retrieved 17 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Tulinovet: Pending EC decision". European Medicines Agency. 17 July 2020. Retrieved 17 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

External links

Pfizer monograph for Draxxin (tulathromycin)

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Draxxin Archived 2006-10-24 at the Wayback Machine at draxxin.com

[Increxxa:_Pending_EC_decision-2] "Increxxa: Pending EC decision". European Medicines Agency. 17 July 2020. Retrieved 17 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Tulinovet:_Pending_EC_decision-3] "Tulinovet: Pending EC decision". European Medicines Agency. 17 July 2020. Retrieved 17 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.